EBQ:CRASH-3 Trial
Revision as of 08:53, 29 October 2019 by ElavemanMD (talk | contribs) (Created page with "{{JC info | title=Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a r...")
Incomplete Journal Club Article
The Crash 3 Trial Collaborators. "Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.". The Lancet. 2019. {{{volume}}}:{{{pages}}}.
PubMed Full text
PubMed Full text
Clinical Question
Is tranexamic acid beneficial in patients with TBI?
Conclusion
"Our results show that tranexamic acid is safe in patients with TBI and that treatment within 3 hours of injury reduces head injury-related death. Patients should be treated as soon as possible after injury"
Major Points
Template:Intracranial Hemorrhage
Design
Population Studied
Inclusion Criteria
Exclusion Criteria
Baseline Characteristics
Interventions
Outcomes
Primary Outcomes
Secondary Outcomes
Adverse events
Tertiary Outcomes
Discussion
Criticism
Funding
National institute for health research health technology assessment, JP Moulton Charitable Trust, Department of Health and Social Care, Department for International Development, Global Challenges Research Fund, Medical Research Council, and Welcome Trust (Joint Global Health Trials Scheme)